Penumbra, Inc.

Penumbra, Inc.

PEN·NYSE

$319.37

+0.20%
HealthcareMedical - Devices

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

At a Glance

Live Snapshot
Market Cap$12.56B
EPS4.5700
P/E Ratio68.10
Earnings Date08/04/2026

pen

Net Income

Last Annual Value

177.69M

3-Year CAGR

349%

5-Year CAGR

68%

10-Year CAGR

54%

Penumbra, Inc.

Penumbra, Inc. Competitors Analysis of Net Income

PEN · NYSE
CompanyNet Income
CAGR 3Y
CAGR 5Y
CAGR 10Y
177.69M
25.0%102.0%28.2% 
128.37M
N/AN/AN/A
410.35M
-2.7%-11.9%8.0%
-957.00M
N/AN/AN/A
537.90M
63.6%29.2%17.8%
215.20M
N/A89.4%29.2%
759.90M
N/A-29.1%39.0%
-144.34M
N/AN/AN/A
398.00M
-1.5%-8.6%-2.4%
DVA logo
DaVita Inc.
NYSE:DVA
746.80M
2.6%-5.3%-1.6%
Penumbra, Inc.

Penumbra, Inc. Fair Value Envelope

PEN · NYSE

Our analysis suggests that PEN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $319.37, this represents a potential HIDDEN relative to our calculated worth for Penumbra, Inc..

Intrinsic Value
Current Price: $319.37